Business Nabors Industries outlines 6%–8% normalized EBITDA growth for 2026 while expanding international rig count and reducing debt
Business Essential Properties outlines 2026 AFFO per share guidance growth up to 8% while capitalizing on resilient credit trends
Business Karyopharm signals $130M–$150M revenue target for 2026 with pivotal myelofibrosis data readout ahead